Polymeric Nanosponges: A Promising Platform for Improving Roflumilast Solubility
DOI:
https://doi.org/10.22270/ajprd.v14i3.1790Abstract
The drug roflumilast, a selective phosphodiesterase-4 enzyme inhibitor that can be used to treat persistent obstructive lung disease (COPD), has limited therapeutic potential due to its poor solubility and bioavailability. The aim of this literature review is to provide an overview of polymeric nanosponges as a novel drug delivery mechanism to enhance the solubility/bioavailability of roflumilast in vivo/vitro. Nanosponges are a type of nanocarrier that can be used to deliver poorly soluble drugs by encapsulating (i.e. solubilizing) these drugs—enhancing drug stability and providing zero order-controlled release. This review examines the fundamental properties of nanosponges including the different types of nanosponges, the preparation methods used to create them, and characterization methods. The role of nanosponges in improving the solubility of roflumilast by increasing surface area, molecular dispersion, and amorphous nature will also be discussed. Several formulation strategies and factors influencing the performance of nanosponges will also be covered. Finally, examples of in vitro and in vivo experiments that show improved solubility/bioavailability of roflumilast using nanosponges will also be presented in this review. In addition, advances in research related to targeted delivery, responsive to stimuli, and environmentally friendly synthesis of nanosponges will be discussed. Although there are barriers to the scale-up production of nanospounges and translational use in the clinic, the potential of polymeric nanosponges as a practical and versatile tool for advancing the therapeutic effectiveness of poorly soluble drugs like roflumilast is considerable.
Downloads
References
Thakur V, Dogra S, Verma S, Vashist H. Solubility enhancement techniques. World J Pharma Res. 2020 Aug 24;9(13):265-82.
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. Journal of pharmacy and pharmacology. 2010 Nov;62(11):1607-21.
H. Muller R, Shegokar R, M. Keck C. 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications. Current drug discovery technologies. 2011 Sep 1;8(3):207-27.
Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. Journal of pharmacy and pharmacology. 2004 Jul;56(7):827-40.
Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein journal of organic chemistry. 2012 Nov 29;8(1):2091-9.
Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. Aaps Pharmscitech. 2011 Mar;12(1):279-86.
Sheng Y, He Y, Huang X, Yang J, Wang K, Zheng Q. Systematic evaluation of dose proportionality studies in clinical pharmacokinetics. Current drug metabolism. 2010 Jul 1;11(6):526-37.
Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. The Lancet. 2005 Jan 8;365(9454):167-75.
Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery. 2016 Jul 2;11(7):733-44.
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. The Lancet. 2009 Aug 29;374(9691):695-703.
Selvamuthukumar S, Anandam S. Nanosponges: A novel class of drug delivery system-review. Journal of Pharmacy & Pharmaceutical Sciences. 2012 Jan 17;15(1):103
Conceicao J, Adeoye O, Cabral-Marques HM, Lobo J. Cyclodextrins as drug carriers in pharmaceutical technology: the state of the art. Current pharmaceutical design. 2018 Apr 1;24(13):1405-33.
Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: A critical review. Carbohydrate polymers. 2017 Oct 1;173:37-49.
Danaei MR, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari YM. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018 May 18;10(2):57.
Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharmaceutical research. 2000 Apr;17(4):397-404.
Kumar, K., Rawat, S.G., Mishra, M., Rani, V., Jadhav, A.P., Kumar, A. and Chawla, R., EGFR and Sialic Acid Binding Receptor Functionalized pH Responsive Chitosan Nanoparticles for Enhanced Active Cellular Internalization of Gemcitabine in NSCLC. Mohini and Rani, Varsha and Jadhav, Atul Pandurang and., Priya and Kumar, Ajay and Chawla, Ruchi, EGFR and Sialic Acid Binding Receptor Functionalized pH Responsive Chitosan Nanoparticles for Enhanced Active Cellular Internalization of Gemcitabine in NSCLC.
Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein journal of organic chemistry. 2012 Nov 29;8(1):2091-9.
Nandi S, Biswas PO. Nanosponge—an emerging nanomaterial in recent advancement of novel drug delivery: An overview and future perspectives. Indian J Pharm Sci. 2024 Mar 1;86(2):392-406.
Rao MR, Sonawane A, Sapate S, Paul G, Rohom S. Nanosponges: A multifunctional drug delivery system. Int. J. All Res. Educ. Sci. Methods (IJARESM). 2021 May;9:2455-6211.
Bachu RD, Chowdhury P, Al-Saedi ZH, Karla PK, Boddu SH. Ocular drug delivery barriers—role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018 Feb 27;10(1):28..
Dabhi FA, Shah VD, Pandya BD. A review on nanosponges: an ascendance of potential nanocarrier for emerging drug delivery. Eur J Pharm Med Res. 2023;10(5):134-47.
Ahmed F, Khan MA, Haider N, Ahmad MZ, Ahmad J. Recent advances in theranostic applications of nanomaterials in cancer. Current Pharmaceutical Design. 2022 Jan 1;28(2):133-50.
Kumar S, Nair AB, Kadian V, Dalal P, Jangir BL, Aldhubiab B, Almuqbil RM, Alnaim AS, Alwadei N, Rao R. Development and evaluation of hydrogel-based sulfasalazine-loaded nanosponges for enhanced topical psoriasis therapy. Pharmaceuticals. 2025 Mar 10;18(3):391.
Pawar AY. Nanosponges: A novel drug delivery system. Asian Journal of Pharmaceutics (AJP). 2016 Dec 21;10(04).
Hariyadi DM, Rosita N. Characterization and antibacterial activity of cocos Nucifera L. Meat extract and powder as a drug and cosmetic agent. International Journal of Research in Pharmaceutical Sciences. 2020;11(1):611-6.
Durai RD. REVIEW ARTICLE Drug delivery approaches of an antiviral drug: A comprehensive review. Asian Journal of Pharmaceutics (AJP). 2015 Jan 15:1-2
Chauhan N, Kumar M, Kumar K, Chopra S, Bhatia A. Exploring innovative approaches in type-2 diabetes management: a comprehensive review on nano-carriers and transdermal drug delivery. Current Pharmaceutical Design. 2024 Jun 1;30(22):1725-45.
Pawar AY. Nanosponges: A novel drug delivery system. Asian Journal of Pharmaceutics (AJP). 2016 Dec 21;10(04).
Thanushree HN, Manjunath K. Design, Optimization And Evaluation Of Buccal Films Of Nicorandil Using Design Of Experiments. World Journal of Pharmaceutical Research.;14(22):667-84.
Goyal N, Amar A, Gulati S, Varma RS. Cyclodextrin-based nanosponges as an environmentally sustainable solution for water treatment: a review. ACS Applied Nano Materials. 2023 Jul 24;6(15):13766-91.
Srinatha N, Battu S, Vishwanath BA. Microsponges: a promising frontier for prolonged release-current perspectives and patents. Beni-Suef University Journal of Basic and Applied Sciences. 2024 Jun 21;13(1):60.Kaur R, Garg T, Rath G, Goyal AK. Nanosponges: a potential carrier. Drug Deliv. 2015;22(6):1–10.
Allahyari S, Trotta F, Valizadeh H, Jelvehgari M, Zakeri-Milani P. Cyclodextrin-based nanosponges as promising carriers for active agents. Expert opinion on drug delivery. 2019 May 4;16(5):467-79.
Kerilos IE, EL-Sawy HS, Elyazid SK, Ibrahim MA. Nanosponge for enhancing solubility and bioavailability of oral drugs. Int J App Pharm. 2024;16(1):9-17.
Challa R, Ahuja A, Ali J, Khar R. Cyclodextrins in drug delivery: an updated review. Aaps Pharmscitech. 2005 Jun;6(2):43.
Stella VJ, He Q. Cyclodextrins. Toxicologic pathology. 2008 Jan;36(1):30-42.
Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. International journal of pharmaceutics. 2007 Feb 1;329(1-2):1-1.
Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Advanced drug delivery reviews. 1999 Mar 1;36(1):17-28.
Zhou J, Ritter H. Cyclodextrin functionalized polymers as drug delivery systems. Polymer Chemistry. 2010;1(10):1552-9.
Del Valle EM. Cyclodextrins and their uses: a review. Process biochemistry. 2004 May 31;39(9):1033-46.
Vyas SP, Khar RK. Targeted & controlled drug delivery: novel carrier systems. CBS publishers & distributors; 2002.
Allen L, Ansel HC. Ansel's pharmaceutical dosage forms and drug delivery systems. Lippincott Williams & Wilkins; 2013 Dec 23.
Taylor KM, Aulton ME, editors. Aulton's pharmaceutics E-Book: The design and manufacture of medicines. Elsevier Health Sciences; 2013 Jul 29.
Sinko PJ. Martin's physical pharmacy and pharmaceutical sciences. Lippincott Williams & Wilkins; 2023 Feb 8.
Remington JP. Remington: the science and practice of pharmacy. Lippincott Williams & Wilkins; 2006.
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and surfaces B: biointerfaces. 2010 Jan 1;75(1):1-8.
Yu BO, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Molecular membrane biology. 2010 Oct 1;27(7):286-98.
Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature reviews Drug discovery. 2014 Nov;13(11):813-27.
Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M. Nanotechnology for breast cancer therapy. Biomedical microdevices. 2009 Feb;11(1):49-63.
Langer R. Drug delivery and targeting. Nature. 1998 May 1;392(6679).
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular pharmaceutics. 2008 Aug 4;5(4):505-15.
Kesisoglou F, Panmai S, Wu Y. Nanosizing—oral formulation development and biopharmaceutical evaluation. Advanced drug delivery reviews. 2007 Jul 30;59(7):631-44.
Merisko-Liversidge E. Nanosizing:“end-to-end” formulation strategy for poorly water-soluble molecules. Discovering and Developing Molecules with Optimal Drug-Like Properties. 2014 Sep 27:437-67.
Rabinow BE. Nanosuspensions in drug delivery. Nature reviews Drug discovery. 2004 Sep 1;3(9):785-96.
Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. European journal of pharmaceutical sciences. 2006 Nov 1;29(3-4):278-87.
Vrettos NN, Roberts CJ, Zhu Z. Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications. Pharmaceutics. 2021 Sep 30;13(10): 1591.
Beyssac E, Cardot JM, Bonnabry C. In vitro/in vivo correlations. InCutaneous Biometrics 2000 (pp. 315-329). Boston, MA: Springer US.
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical research. 1995 Mar;12(3):413-20.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Sarvesh Sharad Bagul, Dr. Deepak D. Sonawane, Mayuri P. Pol, Dr. Sunil. K. Mahajan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 